FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series D or later / Biotech startups that raised Series D or later in Europe

Biotech startups that raised Series D or later in Europe

Updated 16 Nov 2026

Reset
Biotech startups that raised Series D or later in Europe
One-time CSV
  • 42 funded companies, 25 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-d-plus~europe.csv42 rows × 18 columns
CompanyCityLast roundAmountDate
bit.bioCambridgeSeries D$25.0M2026-11-04
CellCentricCambridgeSeries D$220.0M2026-05-06
MedTrace PharmaLyngbySeries F$11.1M2025-05-12
Alentis TherapeuticsAllschwilSeries D$181.4M2024-11-12
CatalYmPlaneggSeries D$150.0M2024-07-16
PhagenesisManchesterSeries D$42.0M2024-03-04
LunaphoreLausanneSeries D$32.7M2023-03-23
iThera MedicalMunichSeries D$13.8M2022-12-21

8 rows of the CSV in 5 of its 18 columns.

42
Startups
$3.1B
Total raised
5
Funded in the last 12 months
$528.7M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

10 of 42
10 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
bit.bio Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. Biotech Cambridge, United Kingdom Series D $25.0M 2026-11-04 $250.0M Metaplanet, Foresite Capital 101 to 250 2016
CellCentric CellCentric develops small molecule therapies for treating cancer and multiple myeloma. Biotech Cambridge, United Kingdom Series D $220.0M 2026-05-06 $475.7M Innovate UK, 5Y Capital, RA Capital Management +2 11 to 50 2003
MedTrace Pharma MedTrace Pharma helps doctors diagnose critically ill patients faster and more accurately. Biotech Lyngby, Denmark Series F $11.1M 2025-05-12 $63.4M European Innovation Council, Vaekstfonden, ATP +1 11 to 50 2015
Alentis Therapeutics Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. Biotech Allschwil, Switzerland Series D $181.4M 2024-11-12 Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 51 to 100 2019
CatalYm CatalYm develops immunotherapies to treat cancer. Biotech Planegg, Germany Series D $150.0M 2024-07-16 $260.9M Bayern Kapital, Forbion Capital Partners, Novartis Venture Fund +1 11 to 50 2016
Phagenesis Phagenesis develops a device that treats dysphagia, a condition that makes swallowing food unsafe. Biotech Manchester, United Kingdom Series D $42.0M 2024-03-04 $71.4M MedTech Innovator, EQT Life Sciences, Northern Gritstone +2 11 to 50 2007
Lunaphore Lunaphore is a life sciences company that creates technologies enabling spatial biology in all laboratories. Biotech Lausanne, Switzerland Series D $32.7M 2023-03-23 Venture Kick, VentureOut, redalpine 11 to 50 2014
iThera Medical iThera Medical develops proprietary MSOT imaging technology for preclinical and clinical applications. Biotech Munich, Germany Series D $13.8M 2022-12-21 $42.3M European Innovation Council, Bayern Kapital, German Federal Ministry of Research, Technology and Space +1 11 to 50 2010
Biosystems International Biosystems International develops blood-based diagnostics for cancer and chronic diseases. Biotech Debrecen, Hungary Series D $2.8M 2020-10-29 Societe Generale Asset Management, Amundi Private Equity Funds 11 to 50 2004
Phenex Pharmaceuticals Phenex Pharmaceuticals discovers and develops novel pharmaceutical drugs. Biotech Heidelberg, Germany Series D $6.5M 2012-10-31 KfW, Creathor Ventures, LBBW VC +2 11 to 50 2002

Table 1. Biotech startups that raised Series D or later in Europe: the 10 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 42.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 CellCentric CellCentric develops small molecule therapies for treating cancer and multiple myeloma. Biotech Cambridge, United Kingdom Series D $220.0M 2026-05-06 $475.7M Innovate UK, 5Y Capital, RA Capital Management +2 11 to 50 2003
2 bit.bio Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. Biotech Cambridge, United Kingdom Series D $25.0M 2026-11-04 $250.0M Metaplanet, Foresite Capital 101 to 250 2016

Table 2. Biotech startups that raised Series D or later in Europe: the 2 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Bayern Kapital Venture capital firm Landshut, Germany 5 12%
2 KfW Government investment office Frankfurt, Germany 3 7%
3 RA Capital Management Startup incubator Boston, United States 2 5% 1 CellCentric
4 European Innovation Council Startup accelerator Brussels, Belgium 2 5%
5 HTGF (High-Tech Gruenderfonds) Venture capital firm Bonn, Germany 2 5%
6 Signet Healthcare Partners Venture capital firm New York, United States 2 5%
7 Novartis Venture Fund Corporate venture arm Basel, Switzerland 2 5%
8 Forbion Capital Partners Private equity firm Naarden, The Netherlands 2 5%
9 EQT Life Sciences Private equity firm Amsterdam, The Netherlands 2 5%
10 Venture Kick Startup incubator Schlieren, Switzerland 2 5%
11 MIG Capital Venture capital firm Munich, Germany 2 5%
12 Foresite Capital Private equity firm San Francisco, United States 1 2% 1 bit.bio
13 Metaplanet Venture capital firm Tallinn, Estonia 1 2% 1 bit.bio
14 5Y Capital Venture capital firm Xuhui, China 1 2% 1 CellCentric
15 Pfizer Corporate venture arm New York, United States 1 2% 1 CellCentric

Table 3. Biotech startups that raised Series D or later in Europe: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 41 98% $3.1B
Software 3 7% $32.3M
Energy 1 2%

Table 4. Biotech startups that raised Series D or later in Europe by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series D+ 42 100% $23.7M

Table 5. Biotech startups that raised Series D or later in Europe by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
United Kingdom 12 29%
Germany 9 21%
Switzerland 6 14%
France 6 14%
Belgium 3 7%
Austria 1 2%
Denmark 1 2%
Ireland 1 2%
Hungary 1 2%
Spain 1 2%
Sweden 1 2%

Table 6. Biotech startups that raised Series D or later in Europe by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Cambridge 5 12%
Paris 3 7%
Manchester 3 7%
Munich 2 5%
Basel 1 2%
Innsbruck 1 2%
Lyngby 1 2%
Allschwil 1 2%
Antwerp 1 2%
Planegg 1 2%
Lausanne 1 2%
Galway 1 2%

Table 7. Biotech startups that raised Series D or later in Europe by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 1 20% $25.0M
October 2026 1 20% $134.7M
June 2026 1 20% $34.0M
May 2026 1 20% $220.0M
November 2025 1 20% $115.0M

Table 8. Biotech startups that raised Series D or later in Europe: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 4 10% $413.7M
2025 3 7% $126.1M
2024 6 14% $562.1M
2023 2 5% $64.9M
2022 3 7% $57.1M
2021 1 2% $88.0M

Table 9. Biotech startups that raised Series D or later in Europe by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2015 to 2019 7 17%
2010 to 2014 7 17%
Before 2010 28 67%

Table 10. Biotech startups that raised Series D or later in Europe by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 1 3%
11 to 50 28 72%
51 to 100 6 15%
101 to 250 3 8%
251 to 500 1 3%

Table 11. Biotech startups that raised Series D or later in Europe by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Europe whose last round is Series D or later are on the list?
42, in the file dated 16 November 2026. 5 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 42 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series D or later in Europe: 42 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Europe

Other sectors that raised Series D or later in Europe

Cite: FundingWatcher, 42 biotech companies in Europe whose most recent round is Series D or later, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-d-plus/europe/